Michael Wang, MD

• Multiple Myeloma

I am a Professor in the department of Lymphoma & Myeloma at MD Anderson. I obtained my M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. I completed my clinical training as a resident at Norwalk Hospital, Norwalk, Conn., and as a Fellow in Oncology and in Hematology at MD Anderson.

I have published more than 150 peer-reviewed papers and have presented my work at meetings nationally and internationally. I am the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.

During the past 15 years, I have focused on preclinical and clinical research and established a MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. My clinical research of the Bruton’s tyrosine kinase inhibitor ibrutinib was published in the New Eng. J. Med. in 2013. I am currently acting as National PI of the multisite international phase 5 registration trial for ibrutinib in MCL. I am also the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.